 Tyler Robin
Concepts (246)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 13 | 2025 | 399 | 3.740 |
Why?
| | Small Cell Lung Carcinoma | 6 | 2023 | 123 | 2.400 |
Why?
| | Prostatic Neoplasms | 11 | 2026 | 981 | 1.870 |
Why?
| | Brain Neoplasms | 10 | 2023 | 1331 | 1.800 |
Why?
| | Brachytherapy | 9 | 2025 | 132 | 1.620 |
Why?
| | Lung Neoplasms | 10 | 2023 | 2668 | 1.450 |
Why?
| | Uterine Cervical Neoplasms | 7 | 2023 | 268 | 1.400 |
Why?
| | Cranial Irradiation | 4 | 2020 | 85 | 1.290 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 6 | 2023 | 1192 | 0.980 |
Why?
| | Prostate-Specific Antigen | 2 | 2021 | 161 | 0.780 |
Why?
| | Radiotherapy, Adjuvant | 4 | 2019 | 222 | 0.710 |
Why?
| | Melanoma | 2 | 2018 | 762 | 0.650 |
Why?
| | Ovarian Neoplasms | 2 | 2025 | 596 | 0.650 |
Why?
| | Standard of Care | 2 | 2021 | 81 | 0.620 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2025 | 1150 | 0.560 |
Why?
| | Oropharyngeal Neoplasms | 2 | 2016 | 56 | 0.540 |
Why?
| | Radiotherapy, Intensity-Modulated | 2 | 2018 | 142 | 0.540 |
Why?
| | Prostatectomy | 1 | 2018 | 94 | 0.540 |
Why?
| | Databases, Factual | 9 | 2024 | 1491 | 0.530 |
Why?
| | CTLA-4 Antigen | 1 | 2018 | 105 | 0.520 |
Why?
| | Radiation Oncology | 1 | 2018 | 82 | 0.520 |
Why?
| | Carcinoma, Adenosquamous | 1 | 2017 | 9 | 0.510 |
Why?
| | Oncologists | 1 | 2018 | 47 | 0.510 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2017 | 19 | 0.510 |
Why?
| | Carcinoma, Mucoepidermoid | 1 | 2017 | 17 | 0.510 |
Why?
| | Nose Neoplasms | 1 | 2017 | 22 | 0.500 |
Why?
| | Paranasal Sinus Neoplasms | 1 | 2017 | 29 | 0.500 |
Why?
| | Chemoradiotherapy | 3 | 2019 | 239 | 0.500 |
Why?
| | Aged | 24 | 2025 | 26217 | 0.480 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2016 | 37 | 0.470 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2018 | 266 | 0.470 |
Why?
| | Antibodies | 1 | 2018 | 397 | 0.470 |
Why?
| | Physician's Role | 1 | 2018 | 225 | 0.460 |
Why?
| | Submandibular Gland | 1 | 2015 | 20 | 0.440 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2017 | 641 | 0.430 |
Why?
| | Protein Tyrosine Phosphatases | 2 | 2014 | 167 | 0.420 |
Why?
| | Clinical Decision-Making | 1 | 2018 | 364 | 0.420 |
Why?
| | Radiotherapy Dosage | 6 | 2025 | 288 | 0.410 |
Why?
| | Adenocarcinoma | 2 | 2021 | 926 | 0.410 |
Why?
| | Prostatic Neoplasms, Castration-Resistant | 2 | 2025 | 53 | 0.410 |
Why?
| | Humans | 54 | 2026 | 145783 | 0.400 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 3 | 2025 | 149 | 0.390 |
Why?
| | Internet | 1 | 2018 | 693 | 0.390 |
Why?
| | Aged, 80 and over | 11 | 2025 | 8347 | 0.380 |
Why?
| | Physician-Patient Relations | 1 | 2018 | 588 | 0.370 |
Why?
| | Neoplasm Staging | 8 | 2026 | 1475 | 0.370 |
Why?
| | Radiotherapy, Image-Guided | 2 | 2025 | 40 | 0.370 |
Why?
| | Proto-Oncogene Protein c-fli-1 | 1 | 2012 | 30 | 0.360 |
Why?
| | RNA-Binding Protein EWS | 1 | 2012 | 31 | 0.360 |
Why?
| | Liver Neoplasms | 1 | 2018 | 777 | 0.350 |
Why?
| | Head and Neck Neoplasms | 1 | 2017 | 561 | 0.350 |
Why?
| | Genital Neoplasms, Female | 2 | 2023 | 99 | 0.340 |
Why?
| | Middle Aged | 23 | 2025 | 36309 | 0.340 |
Why?
| | Combined Modality Therapy | 6 | 2025 | 1271 | 0.330 |
Why?
| | Sarcoma, Ewing | 1 | 2012 | 103 | 0.330 |
Why?
| | Neoadjuvant Therapy | 4 | 2018 | 467 | 0.330 |
Why?
| | Pancreatic Neoplasms | 2 | 2017 | 928 | 0.320 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2012 | 212 | 0.310 |
Why?
| | Female | 29 | 2025 | 79045 | 0.300 |
Why?
| | Bone Neoplasms | 1 | 2012 | 265 | 0.300 |
Why?
| | Healthcare Disparities | 1 | 2016 | 736 | 0.300 |
Why?
| | Androgen Antagonists | 3 | 2024 | 91 | 0.290 |
Why?
| | Male | 24 | 2026 | 73011 | 0.280 |
Why?
| | Endometrial Neoplasms | 2 | 2021 | 205 | 0.270 |
Why?
| | Margins of Excision | 2 | 2019 | 50 | 0.270 |
Why?
| | Hysterectomy | 2 | 2019 | 138 | 0.260 |
Why?
| | Chemoradiotherapy, Adjuvant | 2 | 2017 | 44 | 0.250 |
Why?
| | Retrospective Studies | 12 | 2024 | 17330 | 0.250 |
Why?
| | Neoplasms | 2 | 2020 | 2913 | 0.250 |
Why?
| | Lymph Nodes | 2 | 2021 | 509 | 0.240 |
Why?
| | MicroRNAs | 1 | 2012 | 686 | 0.230 |
Why?
| | Cone-Beam Computed Tomography | 1 | 2025 | 32 | 0.230 |
Why?
| | Survival Analysis | 3 | 2018 | 1378 | 0.230 |
Why?
| | Treatment Outcome | 7 | 2022 | 11794 | 0.220 |
Why?
| | Neoplasm Metastasis | 3 | 2017 | 688 | 0.220 |
Why?
| | DNA-Binding Proteins | 1 | 2012 | 1482 | 0.210 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2019 | 1450 | 0.210 |
Why?
| | Hematuria | 1 | 2024 | 11 | 0.210 |
Why?
| | Carcinoma, Small Cell | 1 | 2024 | 172 | 0.210 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 1969 | 0.200 |
Why?
| | Adult | 14 | 2025 | 40881 | 0.200 |
Why?
| | Fiducial Markers | 1 | 2023 | 9 | 0.190 |
Why?
| | Neoplasms, Second Primary | 1 | 2024 | 102 | 0.190 |
Why?
| | Prognosis | 4 | 2024 | 4330 | 0.190 |
Why?
| | Follow-Up Studies | 5 | 2024 | 5428 | 0.190 |
Why?
| | Medical Oncology | 1 | 2025 | 340 | 0.180 |
Why?
| | Lymphatic Metastasis | 1 | 2021 | 336 | 0.160 |
Why?
| | Young Adult | 8 | 2024 | 14254 | 0.150 |
Why?
| | Breast Neoplasms | 4 | 2019 | 2393 | 0.150 |
Why?
| | Simulation Training | 1 | 2021 | 136 | 0.150 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2018 | 427 | 0.140 |
Why?
| | Carcinosarcoma | 1 | 2018 | 23 | 0.140 |
Why?
| | Aquaporin 4 | 1 | 2019 | 101 | 0.140 |
Why?
| | Proportional Hazards Models | 2 | 2024 | 1330 | 0.140 |
Why?
| | Radiometry | 1 | 2018 | 56 | 0.140 |
Why?
| | Enterococcus faecalis | 1 | 1998 | 29 | 0.140 |
Why?
| | Survival Rate | 3 | 2019 | 2094 | 0.140 |
Why?
| | Urine | 1 | 1998 | 64 | 0.140 |
Why?
| | Necrosis | 1 | 2019 | 244 | 0.130 |
Why?
| | Thyroid Carcinoma, Anaplastic | 1 | 2018 | 37 | 0.130 |
Why?
| | India | 1 | 2018 | 213 | 0.130 |
Why?
| | Biopsy | 1 | 2021 | 1082 | 0.130 |
Why?
| | Uterine Neoplasms | 1 | 2018 | 98 | 0.130 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 1998 | 72 | 0.130 |
Why?
| | Practice Patterns, Physicians' | 2 | 2024 | 1372 | 0.130 |
Why?
| | Statistics, Nonparametric | 1 | 2018 | 428 | 0.130 |
Why?
| | Salvage Therapy | 1 | 2018 | 165 | 0.130 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 1 | 2017 | 38 | 0.120 |
Why?
| | Thymoma | 1 | 2017 | 37 | 0.120 |
Why?
| | Thymus Neoplasms | 1 | 2017 | 30 | 0.120 |
Why?
| | Radiotherapy, Conformal | 1 | 2017 | 74 | 0.120 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 198 | 0.120 |
Why?
| | Alphapapillomavirus | 1 | 2016 | 35 | 0.120 |
Why?
| | Database Management Systems | 1 | 2016 | 51 | 0.120 |
Why?
| | Urinary Tract Infections | 1 | 1998 | 210 | 0.120 |
Why?
| | Machine Learning | 1 | 2021 | 587 | 0.110 |
Why?
| | Organs at Risk | 1 | 2015 | 37 | 0.110 |
Why?
| | Patient Preference | 1 | 2018 | 223 | 0.110 |
Why?
| | Forecasting | 1 | 2017 | 390 | 0.110 |
Why?
| | Organ Sparing Treatments | 1 | 2015 | 37 | 0.110 |
Why?
| | Propensity Score | 1 | 2017 | 377 | 0.110 |
Why?
| | Postoperative Care | 1 | 2017 | 286 | 0.110 |
Why?
| | Drug Administration Schedule | 1 | 2016 | 782 | 0.110 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2015 | 58 | 0.100 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2019 | 1752 | 0.100 |
Why?
| | Patient Selection | 1 | 2018 | 739 | 0.100 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 971 | 0.100 |
Why?
| | Thyroid Neoplasms | 1 | 2018 | 370 | 0.100 |
Why?
| | Radiation Injuries | 1 | 2015 | 149 | 0.100 |
Why?
| | Disease Progression | 2 | 2018 | 2865 | 0.100 |
Why?
| | Tomography, X-Ray Computed | 1 | 2024 | 2770 | 0.100 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1547 | 0.100 |
Why?
| | United States | 8 | 2024 | 16126 | 0.090 |
Why?
| | Quality of Life | 1 | 2025 | 3211 | 0.090 |
Why?
| | Mass Screening | 1 | 2021 | 1361 | 0.090 |
Why?
| | Prospective Studies | 3 | 2025 | 8078 | 0.090 |
Why?
| | Genes, Tumor Suppressor | 1 | 2012 | 85 | 0.090 |
Why?
| | Etoposide | 1 | 2012 | 168 | 0.090 |
Why?
| | Cardiovascular Diseases | 1 | 2024 | 2191 | 0.090 |
Why?
| | Adolescent | 7 | 2024 | 22577 | 0.080 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2014 | 457 | 0.080 |
Why?
| | Internship and Residency | 1 | 2021 | 1269 | 0.080 |
Why?
| | Feasibility Studies | 1 | 2015 | 1115 | 0.080 |
Why?
| | Cell Line, Tumor | 3 | 2018 | 3551 | 0.080 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2968 | 0.080 |
Why?
| | Risk Assessment | 3 | 2026 | 3752 | 0.080 |
Why?
| | Colorectal Neoplasms | 1 | 2018 | 868 | 0.080 |
Why?
| | Doxorubicin | 1 | 2012 | 403 | 0.080 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2011 | 220 | 0.080 |
Why?
| | ErbB Receptors | 2 | 2023 | 635 | 0.080 |
Why?
| | Transforming Growth Factor beta | 1 | 2012 | 474 | 0.070 |
Why?
| | Cell Movement | 1 | 2014 | 963 | 0.070 |
Why?
| | Molecular Targeted Therapy | 1 | 2012 | 441 | 0.070 |
Why?
| | Cell Survival | 1 | 2012 | 1104 | 0.070 |
Why?
| | Nuclear Proteins | 1 | 2014 | 740 | 0.070 |
Why?
| | Antineoplastic Agents | 2 | 2016 | 2219 | 0.070 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2012 | 883 | 0.060 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 2006 | 149 | 0.060 |
Why?
| | Infant, Newborn | 2 | 2017 | 6465 | 0.060 |
Why?
| | Scattering, Radiation | 1 | 2025 | 98 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 6085 | 0.050 |
Why?
| | Thiohydantoins | 1 | 2024 | 5 | 0.050 |
Why?
| | Androstenes | 1 | 2024 | 16 | 0.050 |
Why?
| | Phenylthiohydantoin | 1 | 2024 | 44 | 0.050 |
Why?
| | Androgen Receptor Antagonists | 1 | 2024 | 35 | 0.050 |
Why?
| | Cystoscopy | 1 | 2024 | 21 | 0.050 |
Why?
| | Infant | 2 | 2017 | 10091 | 0.050 |
Why?
| | Benzamides | 1 | 2024 | 226 | 0.050 |
Why?
| | Cell Proliferation | 2 | 2012 | 2514 | 0.050 |
Why?
| | Nitriles | 1 | 2024 | 211 | 0.050 |
Why?
| | Hormones | 1 | 2023 | 135 | 0.050 |
Why?
| | Child, Preschool | 2 | 2017 | 11868 | 0.050 |
Why?
| | Child | 3 | 2021 | 22740 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2025 | 740 | 0.040 |
Why?
| | Developing Countries | 1 | 2023 | 317 | 0.040 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2022 | 231 | 0.040 |
Why?
| | Health Care Costs | 1 | 2024 | 425 | 0.040 |
Why?
| | Species Specificity | 2 | 1998 | 546 | 0.040 |
Why?
| | Pyrazoles | 1 | 2024 | 517 | 0.040 |
Why?
| | Ultrasonography | 1 | 2024 | 788 | 0.040 |
Why?
| | Pilot Projects | 1 | 2025 | 1898 | 0.040 |
Why?
| | Yersinia Infections | 1 | 1979 | 3 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 2 | 2024 | 3916 | 0.040 |
Why?
| | Colony Count, Microbial | 1 | 1998 | 89 | 0.030 |
Why?
| | Luminescence | 1 | 2018 | 37 | 0.030 |
Why?
| | Bacteriological Techniques | 1 | 1998 | 66 | 0.030 |
Why?
| | Culture Media | 1 | 1998 | 161 | 0.030 |
Why?
| | Gene Rearrangement | 1 | 2018 | 156 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2018 | 246 | 0.030 |
Why?
| | SEER Program | 1 | 2018 | 230 | 0.030 |
Why?
| | Mice, Nude | 1 | 2018 | 680 | 0.030 |
Why?
| | Regression Analysis | 1 | 2019 | 1001 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2021 | 2123 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2023 | 3418 | 0.030 |
Why?
| | Curriculum | 1 | 2021 | 1074 | 0.030 |
Why?
| | Liver | 1 | 2023 | 1899 | 0.030 |
Why?
| | Spectrophotometry, Ultraviolet | 1 | 2014 | 81 | 0.030 |
Why?
| | Calorimetry | 1 | 2014 | 69 | 0.030 |
Why?
| | Allosteric Regulation | 1 | 2014 | 99 | 0.030 |
Why?
| | Molecular Docking Simulation | 1 | 2014 | 119 | 0.030 |
Why?
| | Magnesium | 1 | 2014 | 157 | 0.020 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2014 | 387 | 0.020 |
Why?
| | Clinical Competence | 1 | 2021 | 1247 | 0.020 |
Why?
| | Logistic Models | 1 | 2018 | 2139 | 0.020 |
Why?
| | Time Factors | 1 | 2024 | 7134 | 0.020 |
Why?
| | Crystallography, X-Ray | 1 | 2014 | 486 | 0.020 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2014 | 347 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2012 | 175 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1777 | 0.020 |
Why?
| | Cohort Studies | 1 | 2021 | 6033 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2014 | 821 | 0.020 |
Why?
| | Brain | 1 | 2022 | 2969 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2014 | 2131 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2014 | 2883 | 0.020 |
Why?
| | Registries | 1 | 2018 | 2410 | 0.020 |
Why?
| | Cell Line | 1 | 2014 | 2823 | 0.020 |
Why?
| | Protein Binding | 1 | 2014 | 2240 | 0.020 |
Why?
| | Neoplastic Stem Cells | 1 | 2011 | 409 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2018 | 4568 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2012 | 1062 | 0.020 |
Why?
| | Cyclin B1 | 1 | 2006 | 5 | 0.020 |
Why?
| | Cyclin B | 1 | 2006 | 15 | 0.020 |
Why?
| | Cyclin A | 1 | 2006 | 17 | 0.020 |
Why?
| | Maleimides | 1 | 2006 | 21 | 0.020 |
Why?
| | Cyclin E | 1 | 2006 | 23 | 0.020 |
Why?
| | G2 Phase | 1 | 2006 | 39 | 0.020 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2006 | 106 | 0.010 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2006 | 70 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2006 | 136 | 0.010 |
Why?
| | Flavonoids | 1 | 2006 | 85 | 0.010 |
Why?
| | Epithelial Cells | 1 | 2012 | 1134 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2006 | 172 | 0.010 |
Why?
| | Protein Kinase C | 1 | 2006 | 251 | 0.010 |
Why?
| | Cell Division | 1 | 2006 | 757 | 0.010 |
Why?
| | Risk Factors | 1 | 2019 | 10919 | 0.010 |
Why?
| | Apoptosis | 1 | 2012 | 2444 | 0.010 |
Why?
| | Animals | 2 | 2018 | 38102 | 0.010 |
Why?
| | Indoles | 1 | 2006 | 507 | 0.010 |
Why?
| | Phosphorylation | 1 | 2006 | 1708 | 0.010 |
Why?
| | Mice | 1 | 2018 | 18356 | 0.010 |
Why?
| | Protein Kinase Inhibitors | 1 | 2006 | 981 | 0.010 |
Why?
| | Yersinia | 1 | 1979 | 2 | 0.010 |
Why?
| | Serotyping | 1 | 1979 | 31 | 0.010 |
Why?
| | New York City | 1 | 1979 | 85 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 5224 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2006 | 2805 | 0.010 |
Why?
|
|
Robin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|